Early evidence shows a potential for eRapa™ to prevent the progression and recurrence of prostate and bladder cancer, meeting a significant unmet need in the marketplace.
Prostate Cancer Unmet Medical Need
• In 2016. ~181,000 US and 1.1 million global new prostate cancer patients; ~26,000 US deaths
• ~60% are diagnosed as low risk – eRapa target
• Men with low risk cancers (Gleason <7) under active surveillance have no effective therapies to slow or prevent cancer progression …only waiting often leading to overtreatment eRapa global market forecast: $1 billion
A majority of men elect premature surgical and/or radiation treatment regardless of the disease severity. 90% of treated patients experience erectile dysfunction, impotency, bowel distress, and other side effects. There are currently no approved medical therapies that have been shown to decrease the rate of progression for men under active surveillance.
U.S. Incidence: 181,000/yr.
Global Incidence: 1.1 million/yr.
U.S. Prevalence: 3.3 million men Price & Reimbursement: Value driven maintenance pricing (~$9k/year)
eRapa positioned as preventive for men with low risk Gleason Score <7
Bladder Cancer Unmet Medical Need
• In 2016, ~77,000 new cases of bladder cancer and carcinoma and
• Approximately 70% will be non-muscle invasive bladder cancer (NMIBC)-eRapa target
• Standard of care, intravesical BCG immunotherapy, & continued surgeries due to high recurrence make bladder cancer one of the most costly cancers to treat eRapa global market forecast: $1 billion
eRapa targets: Tis, Ta, T1 (85%)
Standard of care: Bacillus Calmette- Guérin immunotherapy (BCG)
High % BCG intolerance and non-compliance Progression rate: 50%;
Recurrence rate: 50%
eRAPA POSITIONED AS AN ADJUNCT TO BCG
U.S. Incidence: 77,000/yr.
Global Incidence: 430,000/yr.
U.S. Prevalence: 500,000 Price & Reimbursement: Value driven maintenance pricing (~$9k/year)